New Data on the GlycoMark® Test In Patients Taking SGLT-2 Inhibitors To Be Presented at the American Diabetes Association 79th Scientific Sessions

Posted on June 4, 2019 by


New York, NY (June 4, 2019) — GlycoMark, Inc. announces new data on the GlycoMark® test in patients on SGLT-2 inhibitors are being presented June 8 – 10 at the American Diabetes Association (ADA) Scientific Sessions 2019 in San Francisco.  The GlycoMark test, an FDA-cleared and CE-marked blood test used to monitor glycemic control in patients with diabetes, is uniquely sensitive and specific to detecting high blood glucose levels and glucose variability occurring during the prior 1 to 2 weeks.  A low (abnormal) GlycoMark result indicates poor glucose control including postprandial glucose variability, which can be missed in up to 40% of patients with a “good” A1C.1  The new study “GlycoMark 1,5-Anhydroglucitol Values in Patients Taking SGLT-2 Inhibitors”will be on display in the Clinical Therapeutics/New Technology–SGLT Inhibitors poster sessions Hall F, North, Exhibition Level, June 8 - 10, and attended by GlycoMark Clinical Affairs and study co-author on Sunday, June 9 from 12 - 1 p.m.  For interviews or to schedule a meeting with GlycoMark during the ADA Scientific Sessions, please email GlycoMark@L3healthcare.com.

The GlycoMark Test has not been FDA cleared for monitoring SGLT-2 inhibitor effect.  The GlycoMark test is for professional use, and is indicated for the intermediate term monitoring of glycemic control in people with diabetes.

Reference: 1. Erlinger TP, Brancati FL. Diabetes Care. 2001 Oct;24(10):1734-8.

 

About GlycoMark, Inc.

GlycoMark, Inc., based in Manhattan, New York, is dedicated to improving the management and health of patients with diabetes.  The company is a joint venture among Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan), and is the exclusive supplier of the GlycoMark test in the U.S., Europe, Australia, the Asia-Pacific Region and the Middle East.  The GlycoMark test is an FDA-cleared, non-fasting blood test that detects hyperglycemia and hyperglycemic excursions occurring in the prior 1 to 2 weeks.  Since its discovery, the GlycoMark test, a quantitative test for 1,5-Anhydroglucitol (1,5-AG), has been described in more than 1,300 scientific and medical publications and is shown to be independently associated with complications of diabetes. More information is available at www.GlycoMark.com.

GlycoMark, Inc. is the exclusive licensee of the GlycoMark test, trademark and logo.

 

MEDIA CONTACT

Lauren Lehman, Marketing and Partner Relations
lauren_lehman@glycomark.com
858-437-1107